Insulin therapies: Current and future trends at dawn
- 1 January 2013
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 4 (1), 1-7
- https://doi.org/10.4239/wjd.v4.i1.1
Abstract
Insulin is a key player in the control of hyperglycemia for type 1 diabetes patients and selective individuals in patients of type 2 diabetes. Insulin delivery systems that are currently available for the administration of insulin include insulin syringes, insulin infusion pumps, jet injectors and pens. The traditional and most predictable method for the administration of insulin is by subcutaneous injections. The major drawback of current forms of insulin therapy is their invasive nature. To decrease the suffering, the use of supersonic injectors, infusion pumps, sharp needles and pens has been adopted. Such invasive and intensive techniques have spurred the search for alternative, more acceptable methods for administering insulin. Several non-invasive approaches for insulin delivery are being pursued. The newer methods explored include the artificial pancreas with closed-loop system, transdermal insulin, and buccal, oral and pulmonary routes. This review focuses on the new concepts that are being explored for use in futureKeywords
This publication has 61 references indexed in Scilit:
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialThe Lancet, 2012
- Exubera inhaled insulin: a reviewInternational Journal of Clinical Practice, 2004
- A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitusClinical Therapeutics, 2003
- Insulin: Discovery and ControversyClinical Chemistry, 2002
- HYPOGLYCAEMIC EFFECT OF A NOVEL INSULIN BUCCAL FORMULATION ON RABBITSPharmacological Research, 2002
- Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivoInternational Journal of Pharmaceutics, 2002
- Formulation pH modulates the interaction of insulin with chitosan nanoparticlesJournal of Pharmaceutical Sciences, 2002
- TechnosphereTM/Insulin - proof of concept study with a new insulin formulation for pulmonary deliveryExperimental and Clinical Endocrinology & Diabetes, 2002
- The MiniMed Continuous Glucose Monitoring System (CGMS).1999
- One to Five Days of Continuous Intravenous Insulin Infusion on Seven Diabetic PatientsDiabetes, 1974